[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"allergic-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:allergic-diseases":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,50,88,113,149],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100633879","probiotic-intervention-on-the-development-of-allergic-diseases-in-infants-exposed-to-antibiotics-early-in-life-100633879",false,"NCT07532421","Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life","A Study on the Impact of Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life","Inclusion Criteria:\n\n* Gestational age from 37 weeks to less than 41 weeks;\n* Birth weight between the 10th and 90th percentiles for gestational age;\n* Breastfed (exclusively breastfed after achieving stable feeding volume, with willingness to maintain exclusive breastfeeding for at least 3 months);\n* Postnatal age within 35 days; Consent to participate in this study.\n\nExclusion Criteria:\n\n* Postnatal Apgar score \\\u003C7;\n* Presence of severe congenital malformations or inherited metabolic diseases;\n* Use of probiotics by the infant or the mother within 2 weeks before enrollment.",true,"ALL","1 Day","35 Days",{"count":21,"type":22},400,"ESTIMATED","INTERVENTIONAL",[25],"NA","Early antibiotic exposure is an important environmental factor that disrupts the establishment of the infant gut microbiota and leads to microbial dysbiosis. Accumulating epidemiological evidence indicates that exposure to antibiotics early in life (including both prenatal and postnatal periods) is significantly associated with an increased risk of allergic diseases in childhood. As live microorganisms, probiotics hold potential as a preventive strategy against allergies due to their ability to stabilize the intestinal barrier and regulate immune balance (e.g., promoting Th1\u002FTh2 balance, inducing regulatory T cells, and increasing sIgA secretion). However, current studies have mostly focused on general or high-risk infant populations. For the specific high-risk subgroup that has already been exposed to antibiotics early in life, high-quality randomized controlled trial evidence is still lacking regarding whether probiotic intervention can effectively reduce the incidence of allergies and whether it exerts its effects by reshaping the gut microbiota and metabolites disrupted by antibiotics.\n\nThis study focuses on breastfed infants who received antibiotics during the early postnatal period (within 30 days after birth) and aims to investigate the effect of a probiotic mixture containing Bifidobacterium longum subsp. infantis R0033, Lactobacillus helveticus R0052, and Bifidobacterium bifidum R0071 on the development of allergic diseases after antibiotic exposure.",[28,29,30,31],"Antibiotic","Allergic Diseases","Infants","Probiotic",[33,34,35,36],"probiotics","infants","early postnatal antibiotic exposure","allergic diseases","NOT_YET_RECRUITING","2026-05-06",{"date":40,"type":41},"2026-05-11","ACTUAL",{"date":43,"type":22},"2026-04-17",{"date":45,"type":22},"2027-10-31",{"name":47,"class":48},"Peking University Third Hospital","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":87},"100624893","phase-2-phase-2-study-of-lesigercept-in-adult-patients-with-chronic-spontaneous-urticaria-who-are-inadequately-controlled-by-h1-antihistamines-100624893","NCT07415551","Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines (CLEAR)","CLEAR","Inclusion Criteria:\n\n* Chronic spontaneous urticaria for ≥6 months, uncontrolled on 2nd-generation H1-antihistamines (UAS7≥16, ISS7≥8, HSS7≥8).\n* Stable dose of 2nd-generation H1-antihistamines for ≥7 days; symptom diary compliance ≥80%.\n* Adults 18-75 years; informed consent signed; contraception and pregnancy test requirements for both genders.\n* ≥80% adherence to antihistamines during screening.\n\nExclusion Criteria:\n\n* Any medical or lab findings suggesting risk of worsening co-existing conditions during the study.\n* Clinically significant cardiovascular, neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematologic, gastrointestinal, or immunodeficiency disorders that may compromise safety or study results.\n* History of malignancy within 5 years (except certain cured skin\u002Fcervical cancers) or chronic urticaria with known etiology other than CSU (e.g., inducible urticaria, autoimmune diseases).\n* Active or high-risk parasitic infections, chronic\u002Frecurrent infections (e.g., TB, HBV, HCV, HIV), or hypersensitivity\u002Fanaphylaxis to study drugs or related classes.\n* Skin diseases affecting assessments (e.g., atopic dermatitis, psoriasis) or history of drug\u002Falcohol abuse within 6 months.","18 Years","75 Years",{"count":61,"type":22},150,[63],"PHASE2","This study aims to evaluate the efficacy and safety of lesigercept in approximately 150 participants with CSU. By enrolling participants with an inadequate response to H1-antihistamines, including those previously treated with omalizumab, this study is expected to provide evidence for the clinical utility of lesigercept and to further characterize its benefit-risk profile in the target participant population.",[29,66],"Chronic Spontaneous Urticaria (CSU)",[68,69,70,71,72,73,74,75],"CSU","YH35324","Allergic disease","Chronic Spontaneous Urticaria","Yuhan","GI-301","Lesigercept","M9010","RECRUITING","2026-04-12",{"date":79,"type":41},"2026-04-15",{"date":81,"type":41},"2026-03-26",{"date":83,"type":22},"2027-07-24",{"name":85,"class":86},"Yuhan Corporation","INDUSTRY",30,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":17,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":23,"phases":99,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":4},"100632451","phase-1-trial-of-jyb1904-injection-in-adolescent-participants-100632451","NCT07513857","Trial of JYB1904 Injection in Adolescent Participants","A Multicenter, Single-arm, Phase Ib Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Profiles of JYB1904 Injection in Adolescent Participants Aged 12-17 Years","Inclusion Criteria:\n\n* Adolescent study participants (both male and female) who are at least 12 years of age but under 18 years of age at the time of signing the Informed Consent Form (ICF).\n* History of allergic diseases, including but not limited to food allergies, allergic rhinitis, allergic asthma, and chronic spontaneous urticaria.\n* Body weight ≥ 30 kg at screening.\n* Agreement to use effective contraception during the study and for 1 year following administration of the study drug.\n* The trial participant and their parent or legal guardian are able to understand and voluntarily sign the Informed Consent Form, and are able to comply with study visits and related procedures.\n\nExclusion Criteria:\n\n* Patients with a history of hypersensitivity to JYB1904 Injection, its excipients, or any anti-IgE therapy.\n* Any severe or poorly controlled chronic disease (including but not limited to severe arrhythmia, ischemic heart disease, NYHA Class III\u002FIV left ventricular failure, severe pulmonary disease, poorly controlled asthma, poorly controlled hypertension, poorly controlled diabetes, or poorly controlled hypothyroidism or hyperthyroidism) that, in the investigator's judgment, may compromise the safety of the trial participant.\n* History of severe allergic reactions, such as anaphylactic shock.\n* History of blood phobia, needle phobia, or difficulty with venipuncture; or abnormal skin at the administration site that may interfere with drug administration or the investigator's assessment (e.g., skin lesions, rashes, tattoos, etc.).\n* Total blood loss or blood donation of ≥400 mL within 12 weeks prior to screening, or receipt of a blood transfusion within 12 weeks prior to screening.","12 Years","17 Years",{"count":98,"type":22},12,[100],"PHASE1","This Phase Ib Trial is Meant to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Profiles of JYB1904 Injection in Adolescent Participants With Allergic Diseases.",[29],[29],"2026-04-01",{"date":106,"type":41},"2026-04-07",{"date":108,"type":22},"2026-05-17",{"date":110,"type":22},"2027-07-30",{"name":112,"class":86},"Jemincare",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":119,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":23,"phases":123,"briefSummary":124,"conditions":125,"keywords":129,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":142,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":49},"100558150","dietary-intervention-on-atopy-100558150","NCT06547372","Dietary Intervention on Atopy","Inclusion Criteria:\n\n1. Presence of current, mild-to-moderate atopic dermatitis\u002Feczema at flexural areas\n2. 21 to 65 years of age (inclusive) at screening\n3. Must be English-literate and able to give informed consent in English\n4. Be residing in Singapore and will not be travelling outside of Singapore during the study period\n5. Reliable and willing to follow study procedures and be available for the duration of the study\n6. Non-smokers (tobacco and e-cigarette)\n7. Non-drinker (no regular or frequent consumption of alcohol)\n8. Overtly healthy with no pre-existing medical conditions (e.g., diabetes, hypertension, cancer, blood disorders, degenerative\u002Fliver\u002Fautoimmune\u002Fimmune\u002Frenal diseases, or psychiatric conditions)\n9. No food allergies to test foods\n10. No needle phobia\n11. Be willing to follow the instruction provided by the investigators on the use of any moisturiser, cosmetics, and\u002For topical cream on the skin throughout the entire duration of the study.\n\nExclusion Criteria:\n\n1. Concurrent participation in other research studies\n2. Pregnancy or lactating individuals\n3. Known or ongoing psychiatric disorders within 3 years\n4. Known severe nutritional deficiency\n5. Vegetarian\u002Fvegans (as meat will be included in the diet)\n6. Individuals who made a significant dietary change in the past 12 months\n7. Having a pre-existing dietary restriction that would interfere with the adherence to a whole diet meal\n8. Regular use of strong medication (western and\u002For traditional), therapies, and alternative medications\n9. Regular nutritional supplements in the past 12 months Regular consumption of oral contraceptive pills and\u002For steroid hormones\n10. Antibiotic use in the past 2 months\n11. Any long-term hospitalisation or surgery during the 6 months before enrolment in study\n12. Significant change in weight (+\u002F- 5.0%) during the past month\n13. History of bleeding diathesis or coagulopathy (or any bleeding disorders)\n14. Having donated blood of more than 500 mL within 4 weeks of study enrolment","21 Years","65 Years",{"count":122,"type":22},110,[25],"Diet is a key determinant of overall health, with growing evidence associating dietary patterns with allergic diseases. Among these, atopic dermatitis (AD) is of particular interest as it often represents the earliest manifestation of the atopic triad. Investigating dietary interventions in AD therefore provides a relevant model to better understand how diet may influence the onset and progression of allergic disease more broadly.",[126,127,29,128],"Atopic Dermatitis","Atopic","Allergic Rhinitis",[130,131,132,133,134,135,136,137,138,139,140,141],"Atopic dermatitis","My Healthy Eating Plate","eczema","healthy diet","diet","meals","foods","allergic","allergy","atopic","Singapore","nutrients",{"date":104,"type":41},{"date":144,"type":41},"2024-05-10",{"date":146,"type":22},"2027-12-31",{"name":148,"class":48},"National University of Singapore",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":159,"phases":4,"briefSummary":160,"conditions":161,"keywords":164,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":49},"100519009","biobanking-for-biomarkers-in-respiratory-disease-allergic-diseases-andor-mast-cell-disorders-100519009","NCT06037967","Biobanking for Biomarkers In Respiratory Disease, Allergic Diseases and\u002For Mast Cell Disorders","BIRD-A","Inclusion Criteria:\n\n* patients with a positive prick test or specific IgE regardless of the allergen\n* patients suspected of allergic pathology defined by the need to carry out a prick test or specific IgE or a food or drug reintroduction test as part of the treatment\n* patients with systemic or cutaneous mastocytosis according to the international classification8\n* patients with mast cell activation syndrome according to the international classification8\n* patients with familial hyper-alpha tryptasemia on the presence of variation in the number of copies of the alpha allele of the TPSAB1 gene\n* patients with asthma of any severity\n* people affiliated or beneficiaries of a social security scheme\n* patients able to receive and understand the information on the study and their participation and having freely consented to it in writing before any collection of samples or data necessary for the research (no restriction of rights by the judicial authorities and mastery of the French language).\n\nExclusion Criteria:\n\n* patients under legal protection, guardianship or curatorship\n* pregnant or breastfeeding women","100 Years",{"count":158,"type":22},3200,"OBSERVATIONAL","This study aims to build up a clinico-biological bank of samples from patients suspected of or suffering from allergic diseases (including asthma) or mast cell diseases in order to support future research in the field of allergic diseases. The biobank will help to identify new prognostic, diagnostic and\u002For predictive biomarkers.",[29,162,163],"Asthma","Mast Cell Disorders",[165,166,167,168,169],"Allergy","asthma","mast cell disorders","biomarkers","biobank","2024-04-29",{"date":172,"type":41},"2024-05-01",{"date":174,"type":41},"2024-02-28",{"date":176,"type":22},"2038-06",{"name":178,"class":48},"University Hospital, Toulouse"]